Transcriptional Activity of TAL1 in T Cell Acute Lymphoblastic Leukemia (T-ALL) Requires RBTN1 or -2 and Induces TALLA1, a Highly Specific Tumor Marker of T-ALL*

(Received for publication, June 11, 1996, and in revised form, November 14, 1996)

Yuichi Ono , Norio Fukuhara and Osamu Yoshie Dagger

From the Shionogi Institute for Medical Science, 2-5-1 Mishima, Settsu-shi, Osaka 566, Japan

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

TAL1, which is frequently activated in T cell acute lymphoblastic leukemia (T-ALL), encodes lineage-specific basic helix-loop-helix (bHLH) proteins that bind specifically to E-box DNA motif upon dimerization with ubiquitous basic helix-loop-helix proteins E47 or E12. RBTN1 and RBTN2, also frequently activated in T-ALL, encode proteins only with tandem cysteine-rich LIM domains. We found that aberrant expression of TAL1 detected in 11 out of 14 T-ALL cell lines was invariably accompanied by that of either RBTN1 or RBTN2. Forced expression of TAL1 together with RBTN1 or RBTN2, but not TAL1 alone, strongly induced artificial reporter genes in a TAL1/RBTN-negative T-ALL cell line, HPB-ALL. Such collaborative transcriptional activity of TAL1 and RBTN was not, however, observed in non-T cell lines, suggesting further involvement of some T cell-specific cofactors. In this context, we carried out preliminary evaluation of a potential role of the T cell-specific GATA-binding protein, GATA3, in the transcriptional activity of TAL1 and RBTN. We also showed that coexpression of TAL1 and RBTN1 in HPB-ALL strongly induced TALLA1, a highly specific T-ALL marker whose positivity correlated 100% with ectopic expression of TAL1 among various T-ALL cell lines. Collectively, ectopic TAL1 and RBTN1 or -2, together with some endogenous T cell-specific cofactors like GATA3, constitute a highly collaborative set of transcription factors whose aberrant activity in T cells may lead to leukemogenesis by modulating expression of downstream genes such as TALLA1.


INTRODUCTION

TAL1, also called SCL or TCL5, is a gene whose aberrant activation in the T cell lineage by recurrent chromosomal translocations, t(1;14)(p32;q11) and t(1;7)(p32;q35), precise ~90-kilobase pair interstitial chromosomal deletions (tald), and yet other undefined mechanisms is implicated as the major pathway for the development of T cell acute lymphoblastic leukemia (T-ALL)1 (1-3). TAL1 is normally expressed in erythroid, mastocytic, and megakaryocytic lineages of the hematopoietic system but not in T cells (4, 5). TAL1 encodes at least two polypeptides, full-length 42-kDa TAL1alpha (amino acid residues 1-331) and 22-kDa N-terminally truncated polypeptide TAL1beta (amino acid residues 176-331) (6), both containing the basic helix-loop-helix (bHLH) motif, a DNA-binding and protein dimerization domain found in a number of transcription factors. TAL1 proteins, having no intrinsic DNA binding activity, dimerize with the ubiquitously expressed E2A gene products, E47 and E12 (7, 8), and the heterodimers bind to E-box elements (CANNTG) with a preferred sequence of AA<UNL>CAGATG</UNL>GT (9). By using an artificial reporter gene containing multiple copies of the optimal TAL1/E2A binding sequence, transcriptional activity of the TAL1/E47 heterodimer was examined in transiently transfected murine C3H/10T1/2 fibroblasts (10). While the E47 homodimer strongly induced the reporter gene, the TAL1/E47 heterodimer was much less active, suggesting a negative regulatory role of TAL1 (10). So far, nothing is known about genes regulated by TAL1. Transcriptional activity of TAL1 in T cells has not been examined either. Transgenic mice expressing 42-kDa TAL1 in the T cell lineage did not develop tumors nor did mice irradiated and reconstituted with bone marrow cells infected with a recombinant retrovirus encoding TAL1 (11, 12). Such findings may suggest that additional cofactors are necessary for TAL1 to be oncogenic in T cells (13).

RBTN1/TTG1 and RBTN2/TTG2 are genes that also were originally identified from recurrent chromosomal translocations in T-ALL, t(11;14)(p15;q11) and t(11;14)(p13;q11), respectively (14-16). They encode highly related proteins consisting of only two cysteine-rich zinc finger-like LIM domains, which are considered to mediate protein-protein interactions (17). RBTN1 and RBTN2 are mainly expressed in the brain and erythroid lineage cells, respectively, but not in normal T cells (18, 19). Transgenic mice expressing RBTN1 or RBTN2 in T cells developed tumors but at variable frequencies and only after long latency periods (~10 months) (20, 21), again suggesting a need for cofactors.

In normal hematopoiesis TAL1 is considered to function in close collaboration with RBTN2 and a group of GATA binding zinc finger type transcription factors, GATA1 and GATA2 (19). This conclusion comes from their overlapping patterns of expression in developing erythroid cells (4, 5, 18, 22, 23), their proven physical interactions in vitro as well as in vivo (24-26), and a very similar abnormality in the embryonic erythropoiesis that was produced by disruption of each of these genes (27-30). It is thus conceivable that the activity of TAL1 in T cells as a transcriptional and oncogenic protein requires a similar set of transcriptional cofactors. Recently, efficient collaboration of TAL1 and RBTN2 in T cell oncogenesis has indeed been demonstrated in vivo by generating double transgenic mice (31).

Previously we identified a highly specific surface marker of T-ALL designated TALLA1 (32). TALLA1 is a new member of the tetraspans or transmembrane 4 superfamily and normally expressed in neurons, certain vascular endothelial cells, and certain epithelial cells but not at all in any hematopoietic cells including T cells (32).2 The highly frequent ectopic expression of TALLA1 in T-ALL suggests that its aberrant expression is closely related to leukemogenesis of T-ALL. We have not, however, detected any T-ALL-associated genetic changes involving the TALLA1 gene that is located on X chromosome.3 One possibility is that aberrantly activated transcription factors in T-ALL such as TAL1 are responsible for ectopic expression of TALLA1. In the present study, we examined expression of TAL1, RBTN1, and RBTN2 in a panel of 14 human T-ALL cell lines and evaluated transcriptional activity of TAL1 and RBTN by monitoring expression of transfected artificial reporter genes and the endogenous TALLA1 gene. The transcriptional activity of TAL1 indeed requires RBTN1 or RBTN2 together with some other T cell-specific cofactors and induces the TALLA1 gene. Such a highly collaborative set of transcriptional factors may thus lead to development of T-ALL by modulating expression of downstream genes like TALLA1.


EXPERIMENTAL PROCEDURES

Cell Culture

All of the cell lines used in the present study were cultured in RPMI 1640 supplemented with 10% fetal bovine serum. For details of each cell line see Takagi et al. (32).

RT-PCR

Total RNA samples were prepared from various cell lines using Trizol® reagent (Life Technologies, Inc.). The first strand cDNA synthesis was carried out from 1 µg of total RNA in 20 µl of reaction buffer using a RNA PCR kit (Takara Shuzo, Kyoto, Japan). PCR was then set up using 2 µl from the reaction buffer as template in a 50-µl PCR reaction buffer containing 2.5 units of Pfu DNA polymerase (Stratagene). Amplification was carried out by denaturation at 94 °C for 1 min (5 min at the first cycle) and annealing/extension at 70 °C for 5 min. The number of amplification cycles was 30 for TAL1, RBTN1, and E2A; 27 for GATA3; and 35 for RBTN2. Amplified products were electrophoresed on a 1.5% agarose gel and stained with ethidium bromide. The oligonucleotides used as PCR primers were: TAL1, +5'-TCACCACCAACAATCGAGTGAAGAGG-3' and -5'-CTCCTCCTGGTCATTGAGCAGCTTGG-3'; RBTN1, +5'-CGGAGCGCCCGAGATGATGGTGCTGG-3' and -5'-GCAGTCGAGGTGATACACGTTGTCCC-3'; RBTN2, +5'-TCCCTCCCCAATGTCCTCGGCCATCG-3' and -5'-CTCGGGCCTATATCATCCCATTGATC-3'; E2A, +5'-CAGCAGGGTTTCCAGGCCTGAGGTGC-3' and -5'-GCTGCTGTGCGACTCAGTGAAGTGGG-3'; GATA3, +5'-TAAGATCGACGGTCAAGGCAACCACG-3' and -5'-GTGGTGGATGGACGCTTGGAGAAGG-3'.

Transfection and CAT Assay

The cDNAs for TAL1, RBTN1, RBTN2, and GATA3 were amplified from Jurkat or CEM by RT-PCR. The oligonucleotide primers used were as follows: TAL1alpha , +5'-GAGAGTCTAGACTCTCTAAATATGCCCCAGGATGACC-3' and -5'-GAGAGTCTAGAGCTGGATGCCTCAGATGAGAGCTGAC-3'; TAL1beta , +5'-GAGAGTCTAGAAGCCGGATGCCTTCCCTATGTTCACC-3' and -5'-GAGAGTCTAGAGCTGGATGCCTCAGATGAGAGCTGAC-3'; RBTN1, +5'-CGGAGCGCCCGAGATGATGGTGCTGG-3' and -5'-GCGTTACTGAACTTGGGATTCAAAGG-3'; RBTN2, +5'-TCCCTCCCCAATGTCCTCGGCCATCG-3' and -5'-CTCGGGCCTATATCATCCCATTGATC-3'; GATA3, +5'-AGCACAGCCGAGGCCATGGAGGTGAC-3' and -5'-GTGAGCATCGAGCAGGGCTCTAACCC-3'. Amplified cDNAs were cloned into pCRTMII (Invitrogen) and digested with EcoRI. The EcoRI fragments were then cloned into pMIKneo and pMIKhyg, yielding pMIKneoTAL1alpha , pMIKneoTAL1beta , pMIKneoGATA3, pMIKhygRBTN1, and pMIKhygRBTN2. pMIKneo and pMIKhyg, which carry the genes conferring resistance to neomycin and hygromycin B, respectively, were constructed from an efficient eukaryotic expression vector pSRalpha (33) and kindly provided by Dr. K. Maruyama at The Institute of Medical Science, Tokyo University. To make a reporter plasmid tk-CAT, the herpes simplex virus thymidine kinase (tk) minimal promoter (34) was amplified by PCR using tk-F (+5'-GACTGCAGTCAACACGCAGATGCAGTC-3') and tk-R (-5'-GACTGCAGGGTCGCTCGGTGTTCGAGG-3'), digested with PstI, and cloned into the PstI site of pCAT®-Basic (Promega). To make a reporter plasmid tk-TAL1CS-CAT, the double-stranded DNA containing four copies of the optimal TAL1/E2A-binding motif (AACAGATGGT) (9) was prepared by annealing two synthetic oligonucleotides, +5'-GATCCAGAAGCTT<UNL>AACAGATGGT</UNL>CACACG<UNL>ACCATCTGTT</UNL>AAGCTTCTGGGG-3' and -5'-GATCCCCCAGAAGCTT<UNL>AACAGATGG</UNL>TCGTGTG<UNL>ACCATCTGTT</UNL>AAGCTTCTG-3' and cloned in tandem into the HindIII site of tk-CAT. The dominant negative GATA3 KRR mutant (35) was kindly provided by Astar Winoto. Recipient cells (1 × 107) were transfected by electroporation with indicated combinations of plasmids together with 5 µg of pRC/cytomegalovirus-luciferase carrying the luciferase gene under the control of cytomegalovirus promoter. After 72 h cell lysates were prepared and assayed for CAT activity after normalization of transfection efficiency by luciferase activity as described previously (36).

In Vitro Binding Assay

The EcoRI fragments of the RBTN1 cDNA and RBTN2 cDNA were subcloned into the EcoRI site of the maltose-binding protein (MBP) fusion vector pMAL-c (New England Biolabs). The EcoRI fragment of the GATA3 cDNA was subcloned into the EcoRI site of the glutathione S-transferase (GST) fusion vector pGEX-2T (Pharmacia Biotech Inc.). Production of fusion proteins (MBP-RBTN1, MBP-RBTN2, and GST-GATA3) in Escherichia coli BL21 (Novagen) and their purification were carried out following the protocols recommended by the manufacturers. GST alone or GST-GATA3 fusion protein was immobilized onto glutathione-Sepharose 4B (Pharmacia), washed with phosphate-buffered saline, and incubated at 4 °C for 1 h with MBP alone or MBP-RBTN fusion proteins that were preincubated with 1% skim milk in phosphate-buffered saline at 4 °C for 20 min. Beads were spun down to collect supernatants and washed with cold phosphate-buffered saline 5 times. Bound proteins were eluted with 5 mM reduced glutathione. The eluted proteins and supernatants were run on SDS-polyacrylamide gel electrophoresis and analyzed by immunoblotting using anti-MBP (New England Biolabs).

Isolation of Stable Transformants

HPB-ALL cells (1 × 107) were cotransfected by electroporation with pMIKneo or pMIKneoTAL1alpha and pMIKhyg or pMIKhygRBTN1. Cells were seeded into 96-well plates at 5 × 105/ml and cultured under double selection with 600 µg/ml G418 and 400 µg/ml hygromycin B. Rare growing cultures were individually expanded and determined for expression of transfected genes by RT-PCR (see above). Surface expression of TALLA1 was analyzed by flow cytometry on a FACStar Plus (Becton Dickinson) after indirect immunofluorescence staining with monoclonal anti-TALLA1 (B2D) as described previously (32). Northern blot analysis for TALLA1 and glyceraldehyde-3-phosphate dehydrogenase transcripts was also carried out as described previously (32).


RESULTS

Regular Coexpression of TAL1 and RBTN1 or RBTN2 in T-ALL Cell Lines

Ectopic expression of the TAL1 gene in T-ALL is now known to occur much more frequently than previously considered from the incidence of gross chromosomal rearrangements involving the TAL1 gene locus (2). Similarly, ectopic expression of RBTN1 and RBTN2 in T-ALL may be more frequent than the incidence of respective chromosomal translocations (3). Therefore, we examined 14 T-ALL cell lines for expression of TAL1, RBTN1, and RBTN2 together with that of E2A, whose products E47 and E12 are necessary for the TAL1 gene products to form a DNA binding heterodimer (7-10). As shown in Fig. 1, 11 out of 14 T-ALL cell lines were found to express TAL1, supporting a highly frequent aberrant expression of the TAL1 gene in T-ALL (2). Importantly, the same 11 cell lines were found to be exactly the ones that expressed either RBTN1 (2/11) or RBTN2 (9/11). The remaining 3 T-ALL cell lines expressed neither of them. All of the 14 cell lines expressed the E2A gene, which was thus useful as an internal control. The complete concordance of aberrant expression of TAL1 and RBTN1 or RBTN2 in 11 out of 14 T-ALL cell lines was striking, supporting their interdependent transcriptional and oncogenic activity in T cells. It is also notable that the 11 T-ALL cell lines that coexpressed TAL1 and RBTN1 or RBTN2 are exactly the ones that are strongly positive for surface expression of TALLA1, a highly specific tumor marker of T-ALL (32).


Fig. 1. RT-PCR analysis for expression of TAL1, RBTN1, RBTN2, and E2A in human T-ALL cell lines. Total RNA was isolated from the indicated human T-ALL cell lines. For details of these cell lines, see Takagi et al. (32). RT-PCR was carried out for transcripts from TAL1, RBTN2, RBTN1, and E2A. Amplification products were electrophoresed on 1.5% agarose and stained with ethidium bromide.
[View Larger Version of this Image (68K GIF file)]


Transcriptional Activity of TAL1 Requires RBTN1 or RBTN2

No natural target genes regulated by TAL1 are known yet. Hsu et al. (9) have shown that the heterodimers of TAL1 and E47 or E12 specifically bind to an E-box motif in vitro and regulate expression of an artificial reporter gene containing multiple copies of the optimal TAL1/E2A binding motif in murine C3H10T1/2 fibroblasts (10). We therefore decided to use a similar artificial reporter gene system to examine transcriptional activity of TAL1 and RBTN in T cells. The HSV tk minimal promoter (34) was linked to the CAT structural gene in pCAT-Basic (Promega), making tk-CAT, and then a DNA segment containing four copies of the optimal TAL1/E2A-binding site (AACAGATGGT) (9) was inserted into the upstream sequence of the tk promoter, making tk-TAL1CS-CAT. HPB-ALL cells, which expressed E2A but not TAL1, RBTN1, or RBTN2 (Fig. 1), were used as a recipient. Due to alternative translation initiation sites, TAL1 proteins have at least two isoforms containing the bHLH motif, the 42-kDa TAL1alpha and an N-terminally truncated 22-kDa TAL1beta (6). We therefore tested the activity of both polypeptides.

As shown in Fig. 2A, TAL1alpha or TAL1beta alone did not significantly induce expression of the CAT reporter gene from tk-TAL1CS-CAT. RBTN1 or RBTN2 had no effect on the expression of the reporter gene either. In the presence of RBTN1 or RBTN2, however, TAL1 proteins strongly induced the reporter gene. The full-length TAL1alpha and the N-terminally truncated TAL1beta were similarly effective in the presence of RBTN1 or RBTN2. Thus, RBTN1, which is expressed in the brain (18) and RBTN2, which is expressed in erythroid cells like TAL1 (19), both efficiently cooperated with TAL1. Unexpectedly, however, the reporter plasmid with only the tk minimal promoter and without 4 copies of the TAL1/E2A-binding motif (tk-CAT) was also nearly half as much induced by the coexpression of TAL1 and RBTN as tk-TAL1CS-CAT. Computer analysis revealed a single potential E-box element in the HSV tk minimal promoter and as many as 12 potential E-box elements in the pCAT-Basic plasmid itself. Some of these sequences may thus fortuitously function as a TAL1/E2A-binding site. The deletion of the potential E-box element in the tk promoter, however, did not affect induction of tk-CAT by the combination of TAL1 and RBTN (data not shown). The role of any of the E-box-like elements within pCAT-Basic in the induction by TAL1 and RBTN remains to be seen.


Fig. 2. Transcriptional activity of TAL1. HPB-ALL (A) and BALL-1 (B) were cotransfected with 20 µg of a CAT reporter plasmid, tk-TAL1CS-CAT or tk-CAT, and 10 µg of an expression vector without (-) or with indicated inserts. tk-CAT only contains the HSV tk minimal promoter. tk-TAL1CS-CAT further contains four copies of the optimal TAL1/E2A binding E-box motif (AACAGATGGT) (9) in the upstream sequence of the minimal HSV tk promoter. The results are shown as mean ± S.E. of three independent experiments.
[View Larger Version of this Image (20K GIF file)]


We carried out the same transfection assays using a B-ALL cell line, BALL-1. As shown in Fig. 2B, little transcriptional activity of TAL1 proteins on tk-TAL1CS-CAT or tk-CAT was observed in BALL-1 even in the presence of RBTN1 or RBTN2. Similar negative results were obtained with another B cell line Raji or a monocytoid cell line U937 (data not shown). It is therefore likely that the transcriptional activity of TAL1 proteins requires, besides RBTN, still other cofactor(s) specifically present in T cells.

Effect of GATA3 on Transcriptional Activity of TAL1

In the erythroid lineage cells, GATA1 and GATA2, the zinc finger GATA binding transcription factors are expressed at high levels (19), and in close collaboration with TAL1 and RBTN2 they play essential roles in the erythropoietic development and differentiation (27-30). Furthermore, Osada et al. (24) demonstrated direct binding of RBTN2 with TAL1 and GATA2. On the other hand, they observed little significant binding between TAL1 and GATA1 or GATA2 (24). These results suggest that RBTN2 mediates interactions between TAL1 and GATA proteins. Among the GATA proteins, GATA3 is known to be expressed very specifically in the T cell lineage (37). We confirmed this in Fig. 3 where RT-PCR detected the expression of GATA3 in all the T-ALL cell lines tested but not in any other hematopoietic cell lines including BALL-1. Since it was not known whether RBTN1 or RBTN2 was capable of binding to the T cell-specific GATA3, we also examined direct binding of RBTN1 and RBTN2 to GATA3. To do this, GATA3 was expressed as a GST fusion protein, while RBTN1 and RBTN2 were expressed as MBP fusion proteins. GST alone or GST-GATA3 was immobilized by glutathione beads and incubated with MBP alone, MBP-RBTN1, or MBP-RBTN2. Free proteins and bound proteins eluted by glutathione were analyzed by immunoblot with anti-MBP. As shown in Fig. 4, GST-GATA3 but not GST alone retained MBP-RBTN1 and MBP-RBTN2 but not MBP alone. Thus, both RBTN1 and RBTN2 are capable of binding to GATA3. We also examined direct binding between TAL1 and GATA3 by the same protocol using MBP-TAL1 fusion protein and GST-GATA3 fusion protein. We did not observe any direct binding between TAL1 and GATA3 (data not shown).


Fig. 3. RT-PCR analysis for expression of GATA3 and E2A in various human hematopoietic cell lines. Total RNA was prepared from Jurkat, CEM, HPB-ALL, DND4.1 and Molt-4 (all T cell lines), BALL-1 and Raji (B cell lines), U937 (a monocytoid line), HL-60 (a promyelocytic cell line), and K562 (an erythroleukemia cell line). For details of these cell lines, see Takagi et al. (32). RT-PCR was carried out for transcripts from GATA3 and E2A. Amplification products were electrophoresed on 1.5% agarose and stained with ethidium bromide.
[View Larger Version of this Image (45K GIF file)]



Fig. 4. In vitro binding of GATA3 with RBTN1 and RBTN2. GST alone or GST-GATA3 fusion protein was immobilized to glutathione beads and incubated with MBP alone, MBP-RBTN1 fusion protein, or MBP-RBTN2 fusion protein. Unbound and bound fractions were analyzed by immunoblot using anti-MBP after SDS-polyacrylamide gel electrophoresis. The results are representative of two independent experiments.
[View Larger Version of this Image (42K GIF file)]


These results led us to examine the effect of GATA3 on the transcriptional activity of TAL1/RBTN in T cells and non-T cells. For the sake of convenience, we used only the reporter plasmid tk-TAL1CS-CAT in the following experiments. We first examined the effect of GATA3 overexpression on the transcriptional activity of TAL1alpha in HPB-ALL (Fig. 5A). Transfection of GATA3 had no direct effect on the expression of tk-TAL1CS-CAT. GATA3 also did not collaborate with TAL1alpha . On the other hand, GATA3 clearly augmented the collaborative transcriptional activity of TAL1alpha and RBTN1 or RBTN2 by 2-3-fold. We next carried out the same transfection experiment using BALL-1 (Fig. 5B). As already shown in Fig. 2B, coexpression of TAL1alpha and RBTN1 or -2 hardly induced expression of tk-TAL1CS-CAT. The combination of TAL1alpha and GATA3 was, however, found to induce the reporter gene to some extent even without RBTN1 or -2. The combination of TAL1, GATA3, and especially RBTN1 further enhanced expression of the reporter gene to some extent. It should, however, be noted that the levels of induction of the reporter gene in BALL-1 even by the full combination of TAL1, GATA3, and RBTN1 or -2 were still far less than those seen in HPB-ALL by the combination of TAL1 and RBTN1 or -2. Therefore, the exact role of GATA3 as a cofactor in the collaborative transcriptional activity of TAL1 and RBTN needs further evaluation.


Fig. 5. Effect of GATA3 on transcriptional activity of TAL1. HPB-ALL (A) and BALL-1 (B) were cotransfected with 15 µg of a CAT reporter plasmid, tk-CAT or tk-TAL1CS-CAT, and 10 µg of an expression plasmid without (-) or with indicated inserts. tk-CAT only contains the HSV tk minimal promoter. tk-TAL1CS-CAT further contains four copies of the optimal TAL1/E2A-binding E-box motif (AACAGATGGT) (9) in the upstream sequence of the minimal HSV tk promoter. The results are shown as mean ± S.E. of three independent experiments.
[View Larger Version of this Image (21K GIF file)]


Induction of TALLA1 in HPB-ALL Stably Transformed with TAL1alpha and RBTN1

As mentioned above, the aberrant expression of TAL1 in T-ALL cell lines correlates 100% with strong expression of TALLA1, a highly specific tumor marker of T-ALL not detected on normal T cells (32). To examine the role of TAL1 and RBTN in the ectopic expression of TALLA1, we cotransfected HPB-ALL with the following combinations of expression plasmids: pMIKneo + pMIKhyg, pMIKneoTAL1alpha + pMIKhyg, pMIKneo + pMIKhygRBTN1, and pMIKneoTAL1alpha  + pMIKhygRBTN1. Stable transformants were isolated by double selection with G418 and hygromycin B, and expression of TAL1alpha and RBTN1 in each clone was determined by RT-PCR (data not shown). Two representative clones from each combination were then examined for surface TALLA1 by indirect immunofluorescence staining and flow cytometry (Fig. 6A). HPB-ALL clones transformed with vectors only or those expressing either TAL1alpha or RBTN1 alone showed little surface expression of TALLA1. In sharp contrast, HPB-ALL clones coexpressing TAL1alpha and RBTN1 were strongly positive for TALLA1. The two clones coexpressing TAL1alpha and RBTN1 also contained a large quantity of TALLA1 mRNA, whereas clones transfected with vectors only or those expressing either TAL1alpha or RBTN1 alone showed no such accumulation of TALLA1 mRNA (Fig. 6B). These results strongly suggest that the collaborative transcriptional activity of TAL1 and RBTN indeed induces, either directly or indirectly, the TALLA1 gene in T-ALL.


Fig. 6. Induction of TALLA1 in HPB-ALL by TAL1alpha and RBTN1. HPB-ALL was transfected with indicated combinations of expression vectors, and stable transformants were isolated. Expression of TAL1alpha and/or RBTN1 in each clone was determined by RT-PCR (data not shown). Two representative clones for each combination were then analyzed. A, surface expression of TALLA1. Clones were stained for surface TALLA1 by an indirect immunofluorescence staining method using monoclonal anti-TALLA1 (B2D) (32) and analyzed by flow cytometry. Background profiles were determined by staining with fluorescein isothiocyanate-labeled anti-mouse IgG only. B, Northern blot analysis for TALLA1 transcripts. Total RNA samples (15 µg each) from the same clones were analyzed by Northern blot using the 32P-labeled probe for TALLA1 (32). The same filter was reprobed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
[View Larger Version of this Image (20K GIF file)]



DISCUSSION

TAL1, TAL2, and LYL1, whose bHLH domains are most closely related to each other among >60 bHLH proteins so far described, are all identified as the genes activated in T-ALL by recurrent chromosomal translocations (38, 39). It is thus conceivable that these three bHLH proteins have a common mode of action in the leukemogenesis of T cells. RBTN1 and RBTN2, encoding closely related proteins containing only tandem LIM domains, represent another group of genes frequently activated by T-ALL-specific chromosomal translocations (14-16). Wadman et al. (26) reported that TAL1, TAL2, and LYL1 all interacted with RBTN1 and RBTN2. Furthermore, Larson et al. (31) recently reported that double transgenic mice expressing both TAL1 and RBTN2 in T cells developed T cell tumors much more efficiently than those expressing either gene alone (12, 20, 21). RBTNs, which are devoid of intrinsic DNA binding activity, may thus function as an essential cofactor for TAL1 and related bHLH proteins in their transcriptional and oncogenic activity in T cells. In the present study, we have demonstrated that the transcriptional activity of TAL1 in T cells indeed requires RBTN1 or RBTN2.

First, we found that all the T-ALL cell lines expressing TAL1 do coexpress either RBTN1 or RBTN2 with 100% concordance (Fig. 1). Second, forced expression of TAL1 in a T-ALL cell line HPB-ALL strongly activated transcription from an artificial reporter gene under the control of the HSV tk minimal promoter with four copies of the optimal TAL1/E2A binding E-box motif in the upstream sequence (9) only when RBTN1 or RBTN2 was coexpressed (Fig. 2). Third, TALLA1, a highly specific tumor marker of T-ALL (32) whose positivity shows 100% concordance with that of TAL1 among various T-ALL cell lines, was strongly induced by coexpression of TAL1 and RBTN1 in a TALLA1-negative T-ALL cell line HPB-ALL (Fig. 6). Collectively, RBTN1 or RBTN2 is indeed an essential cofactor for the positive transcriptional activity of TAL1 not only on the artificial reporter gene but also, either directly or indirectly, on an endogenous gene TALLA1 in T cells. Thus, the highly frequent ectopic expression of TALLA1 in T-ALL (32) strongly suggests the presence of aberrant collaborative transcriptional activity of TAL1 and RBTN in most T-ALL cases. The finding that mice coexpressing TAL1 and RBTN2 in the T cell lineage efficiently developed T cell tumors (31) further underscores the importance of such collaborative transcriptional activity of TAL1 and RBTN in triggering the oncogenic process of T cells. Studies are now in progress to examine how the TALLA1 gene is induced in T cells by TAL1 and RBTN.

Unexpectedly, the reporter gene with the HSV tk minimal promoter but without the upstream optimal TAL1/E2A-binding elements was also quite efficiently induced by the coexpression of TAL1 and RBTN1 or -2 in HPB-ALL (Fig. 2). We have not yet examined the mechanism of this induction in detail. However, we may point out that there are a number of potential E-box-like elements in the original CAT plasmid (pCAT-Basic), some of which may function as fortuitous TAL1-responsive elements. Alternatively, TAL1 and RBTN may affect, somehow in a highly T cell-specific manner (see below), the expression and/or activity of transcription factors such as Sp1 and CTF that are known to interact with the HSV tk minimal promoter (40). These possibilities are now under investigation.

Surprisingly, TAL1 even in the presence of RBTN1 or RBTN2 hardly induced the artificial reporter genes in non-T cells (Fig. 2). This suggests that the collaborative transcriptional activity of TAL1 and RBTN1 or -2 further requires some other cofactors specifically present in T cells. The fact that tumor-specific translocations involving TAL1, RBTN1, and RBTN2 are highly restricted to T-ALL and not observed in any other types of tumors (3) also supports that some T-cell specific cofactors are essential for the collaborative oncogenic activity of TAL1 and RBTN. In erythroid cells, TAL1 and RBTN2 are known to function in close collaboration with GATA1 or GATA2, the members of GATA-binding zinc finger type transcription factors (19). It is thus possible that the T cell-specific member of the GATA proteins, GATA3 (37) (Fig. 3), may be one of such cofactors in T cells. We showed that RBTN1 and RBTN2 were capable of directly binding to GATA3 in vitro (Fig. 4). We further demonstrated that overexpression of GATA3 in HPB-ALL augmented the collaborative transcriptional activity of TAL1 and RBTN1 or RBTN2 (Fig. 5). In BALL-1, TAL1 with and even without RBTN collaborated with GATA3 to induce the reporter gene (Fig. 5). These results may support that GATA3 is a cofactor for the collaborative transcriptional activity of TAL1 and RBTN1 or -2 in T cells. However, it should also be noted that the observed collaborative transcriptional activities of TAL1, GATA3, and RBTN1 or -2 in BALL-1 were far less than those seen by the combination of TAL1 and RBTN1 or -2 in HPB-ALL. Furthermore, we found that a dominant negative mutant of GATA3 KRR (35) had no inhibitory effect at all on the collaborative transcriptional activity of TAL1 and RBTN in HPB-ALL (data not shown). The KRR mutant, which has three amino acids KRR (305-307) in the region between the two zinc fingers mutated to alanines, was shown to be totally inactive on a reporter gene linked to multiple GATA3-binding sites and to block transactivation of the same reporter gene by wild type GATA1, GATA2, or GATA3 (35). However, the results with the KRR mutant still do not formally exclude the possibility of GATA3 as a cofactor because the KRR mutation may not affect the ability of GATA3 to function as such. Nevertheless, all of these observations may argue against a critical role of GATA3 in the collaborative transcriptional activity of TAL1 and RBTN1 or -2 in T cells. Thus, there may be more relevant cofactors for the TAL1/RBTN transcriptional complex in T cells besides or even independent of GATA3.

Obviously further studies are needed to define cofactors for TAL1 and RBTN in T cells and to identify downstream genes whose expression in T cells is modulated, like TALLA1, by the TAL1/RBTN transcriptional complex. Such studies will lead to better understanding of the leukemogenesis of T cells and to a new therapeutic strategy for T-ALL.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 81-6-382-2612; Fax: 81-6-382-2598; E-mail: osamu.yoshie{at}shionogi.co.jp.
1    The abbreviations used are: T-ALL, T cell acute lymphoblastic leukemia; bHLH, basic helix-loop-helix; TALLA1, T-ALL-associated antigen-1; RT, reverse transcription; PCR, polymerase chain reaction; CAT, chloramphenicol acetyltransferase; HSV, herpes simplex virus; MBP, maltose-binding protein; GST, glutathione S-transferase; tk, thymidine kinase.
2    M. Nagira, N. Fukuhara, and O. Yoshie, manuscript in preparation.
3    N. Fukuhara, M. Nagira, Y. Ono, I. Ishikawa, and O. Yoshie, unpublished data.

Acknowledgments

We thank Dr. K. Maruyama for pMIKneo and pMIKhyg, Dr. Astar Winoto for pc-KRR, Dr. S. Takagi for fluorescence-activated cell sorter analysis, and Dr. Yorio Hinuma and Dr. Masakazu Hatanaka for constant support and encouragement.


REFERENCES

  1. Baer, R. (1993) Semin. Cancer Biol. 4, 341-347 [Medline] [Order article via Infotrieve]
  2. Bash, R. O., Hall, S., Timmons, C. F., Crist, W. M., Amylon, M., Smith, R. G., and Baer, R. (1995) Blood 86, 666-676 [Abstract/Free Full Text]
  3. Rabbitts, T. H. (1994) Nature 372, 143-149 [CrossRef][Medline] [Order article via Infotrieve]
  4. Pulford, K., Lecointe, N., Leroy-Viard, K., Jones, M., Mathieu-Mahul, D., and Mason, D. Y. (1995) Blood 85, 675-684 [Abstract/Free Full Text]
  5. Visvader, J., Begley, C. G., and Adams, J. M. (1991) Oncogene 6, 187-194 [Medline] [Order article via Infotrieve]
  6. Bernard, O., Lecointe, N., Jonveaux, P., Souyri, M., Mauchauffe, M., Berger, R., Larsen, C. J., and Mathieu-Mahul, D. (1991) Oncogene 6, 1477-1488 [Medline] [Order article via Infotrieve]
  7. Hsu, H.-L., Cheng, J.-T., Cheng, Q., and Baer, R. (1991) Mol. Cell. Biol. 11, 3037-3042 [Medline] [Order article via Infotrieve]
  8. Hsu, H.-L., Wadman, I., and Baer, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3181-3185 [Abstract]
  9. Hsu, H.-L., Huang, L., Tsan, J. T., Funk, W., Wright, W. E., Hu, J.-S., Kingston, R. E., and Baer, R. (1994) Mol. Cell. Biol. 14, 1256-1265 [Abstract]
  10. Hsu, H.-L., Wadman, I., Tsan, J. T., and Baer, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5947-5951 [Abstract]
  11. Elwood, N. J., and Begley, C. G. (1995) Cell Growth & Differ. 6, 19-25 [Abstract]
  12. Robb, L., Rasko, J. E. J., Bath, M. L., Strasser, A., and Begley, C. G. (1995) Oncogene 10, 205-209 [Medline] [Order article via Infotrieve]
  13. Elwood, N. J., Cook, W. D., Metcalf, D., and Begley, C. G. (1993) Oncogene 8, 3093-3101 [Medline] [Order article via Infotrieve]
  14. Boehm, T., Foroni, L., Kaneko, Y., Perutz, M. F., and Rabbitts, T. H. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4367-4371 [Abstract]
  15. McGuire, E. A., Hockett, R. D., Pollock, K. M., Bartholdi, M. F., O'Brien, S. J., and Korsmeyer, S. J. (1989) Mol. Cell. Biol. 9, 2124-2132 [Medline] [Order article via Infotrieve]
  16. Royer-Pokora, B., Loos, U., and Ludwig, W.-D. (1991) Oncogene 6, 1887-1893 [Medline] [Order article via Infotrieve]
  17. Rabbitts, T. H., and Boehm, T. (1990) Nature 346, 418 [Medline] [Order article via Infotrieve]
  18. Foroni, L., Boehm, T., White, L., Forster, A., Sherrington, P., Liao, X. B., Brannan, C. I., Jenkins, N. A., Copeland, N. G., and Rabbitts, T. H. (1992) J. Mol. Biol. 226, 747-761 [Medline] [Order article via Infotrieve]
  19. Orkin, S. H. (1995) J. Biol. Chem. 270, 4955-4958 [Free Full Text]
  20. Fisch, P., Boehm, T., Lavenir, I., Larson, T., Arno, J., Forster, A., and Rabbitts, T. H. (1992) Oncogene 7, 2389-2397 [Medline] [Order article via Infotrieve]
  21. McGuire, E. A., Rintoul, C. E., Sclar, G. M., and Korsmeyer, S. J. (1992) Mol. Cell. Biol. 12, 4186-4196 [Abstract]
  22. Aplan, P. D., Nakahara, K., Orkin, S. H., and Kirsch, I. R. (1992) EMBO J. 11, 4073-4081 [Abstract]
  23. Yamamoto, M., Ko, L. J., Leonard, M. W., Beug, H., Orkin, S. H., and Engel, J. D. (1990) Genes Dev. 4, 1650-1662 [Abstract]
  24. Osada, H., Grutz, G., Axelson, H., Forster, A., and Rabbitts, T. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9585-9589 [Abstract]
  25. Valge-Archer, V. E., Osada, H., Warren, A. J., Forster, A., Li, J., Baer, R., and Rabbitts, T. H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8617-8621 [Abstract]
  26. Wadman, I., Li, J., Bash, R. O., Forster, A., Osada, H., Rabbitts, T. H., and Baer, R. (1994) EMBO J. 13, 4831-4839 [Abstract]
  27. Pevny, L., Simon, M. C., Robertson, E., Klein, W. H., Tsai, S.-F., D'Agati, V., Orkin, S. H., and Costantini, F. (1991) Nature 349, 257-260 [CrossRef][Medline] [Order article via Infotrieve]
  28. Shivdasani, R. A., Mayer, E. L., and Orkin, S. H. (1995) Nature 373, 432-434 [CrossRef][Medline] [Order article via Infotrieve]
  29. Tsai, F.-Y., Keller, G., Kuo, F. C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F. W., and Orkin, S. H. (1994) Nature 371, 221-226 [CrossRef][Medline] [Order article via Infotrieve]
  30. Warren, A. J., Colledge, W. H., Carlton, M. B. L., Evans, M. J., Smith, A. J. H., and Rabbitts, T. H. (1994) Cell 78, 45-57 [Medline] [Order article via Infotrieve]
  31. Larson, R. C., Lavenir, I., Larson, T. A., Bear, R., Warren, A. J., Wadman, I., Nottage, K., and Rabbitts, T. H. (1996) EMBO J. 15, 1021-1027 [Abstract]
  32. Takagi, S., Fujikawa, K., Imai, T., Fukuhara, N., Fukudome, K., Minegishi, M., Tsuchiya, S., Konno, T., Hinuma, Y., and Yoshie, O. (1995) Int. J. Cancer 61, 706-715 [Medline] [Order article via Infotrieve]
  33. Takebe, Y., Seiki, M., Fujisawa, J.-I., Hoy, P., Yokota, K., Arai, K.-I., Yoshida, M., and Arai, N. (1988) Mol. Cell. Biol. 8, 466-472 [Medline] [Order article via Infotrieve]
  34. McKnight, S. L., Gravis, E. R., Kingsbury, R., and Axel, R. (1981) Cell 25, 385-398 [Medline] [Order article via Infotrieve]
  35. Smith, V. M., Lee, P. P., Szychowski, S., and Winoto, A. (1995) J. Biol. Chem. 270, 1515-1520 [Abstract/Free Full Text]
  36. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  37. Ho, I.-C., Vorhees, P., Marin, N., Oakley, B. K., Tsai, S.-F., Orkin, S. H., and Leidon, J. M. (1991) EMBO J. 10, 1187-1192 [Abstract]
  38. Mellentin, J. D., Smith, S. D., and Cleary, M. L. (1989) Cell 58, 77-83 [Medline] [Order article via Infotrieve]
  39. Xia, Y., Brown, L., Yang, C. Y.-C., Tsan, J. T., Siciliano, M. J., Espinosa, R., III, Le Beau, M. M., and Baer, R. J. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 11416-11420 [Abstract]
  40. Jones, K. A., Yamamoto, K. R., and Tjian, R. (1985) Cell 42, 559-572 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.